Xebra Brands Announces Warrant Extension
Rhea-AI Summary
Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) has announced an extension of the expiry date for 13,311,731 outstanding warrants. The 2023 Warrants, with an exercise price of $0.10, were initially set to expire on September 6, 2024, then extended to December 31, 2024, and are now being further extended to June 30, 2025, subject to Canadian Securities Exchange approval.
According to Interim CEO Rodrigo Gallardo, several warrant holders have shown interest in exercising their warrants, and this extension will provide time for the process. The funds from these warrants are intended to provide additional capital to support growth and strengthen the company's first-mover advantage in Mexico.
Positive
- Potential incoming capital through warrant exercises at $0.10 per share
- Interest from warrant holders in exercising their warrants
- Strategic position as first-mover in Mexican market
Negative
- Need for extension suggests possible challenges in warrant execution within original timeframe
- Multiple warrant extensions may indicate capital raising difficulties
VANCOUVER, BC / ACCESSWIRE / December 11, 2024 / Xebra Brands Ltd. ("Xebra" or the "Company") (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0), a cannabis company, is pleased to announce that, subject to the approval of the Canadian Securities Exchange, it is extending the expiry date of an aggregate of 13,311,731 outstanding warrants (the "2023 Warrants").
The exercise price of the 2023 Warrants is
"Several of Xebra's warrant holders have expressed interest in exercising their warrants, and this extension provides the necessary time to facilitate that process. The funds from these warrants will provide additional capital to support our growth and strengthen our first-mover advantage in Mexico," said Rodrigo Gallardo, Interim CEO, President and Director.
ON BEHALF OF THE BOARD:
Rodrigo Gallardo
Interim CEO, President and Director
For more information contact:
Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model; its ability to enter into and execute partnerships or joint venture opportunities on acceptable terms; statements regarding expected benefits of partnerships and supply agreements, its ability to provide economic, environmental, social, or any benefits of any type in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS); its ability to satisfy the conditions of authorizations granted by COFEPRIS; its ability to successfully apply for, obtain and retain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell cannabis-infused beverages, wellness products, or other products in Mexico, Canada, or elsewhere, and its related plans and claims, including market interest and availability; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that Xebra expects to take place in the future; general economic conditions; and other risk factors described in the MD&A of the Company for the period ended November 30, 2023. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Xebra as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of Xebra to retain the authorizations granted by COFEPRIS, the inability to successfully complete financings on terms acceptable to Xebra or at all, the inability to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete potential acquisitions, dispositions or joint ventures for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approvals for license applications on terms satisfactory to Xebra. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique. The foregoing list is not exhaustive and Xebra undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect Xebra's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, Xebra. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.
SOURCE: Xebra Brands Ltd
View the original press release on accesswire.com
FAQ
How many warrants did Xebra Brands (XBRAF) extend in December 2024?
What is the new expiration date for Xebra Brands' 2023 Warrants?
What is the exercise price of Xebra Brands' extended warrants?
How will Xebra Brands (XBRAF) use the funds from warrant exercises?
How many times has Xebra Brands extended these warrants?
